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Oral contraceptive (OC) use and risk of breast
cancer - reply
Sir
We thank Dr Tomasson for his comments on our paper
(Tryggvadottir et al, 1997). Our main point was to demonstrate
that an association that is present in a subgroup with a special type
ofexposure can become undetectable when this subgroup is mixed
in with a larger group of subjects lacking this type of exposure.
The purpose of Table 2 was to demonstrate this effect. Another
recent example in the literature in which a similar effect was
suggested was the association between smoking and breast cancer
for a subgroup ofwomen with polymorphism in the N-acetyltrans-
ferase 2 gene leading to slow acetylation (Ambrosone et al, 1996),
an association that is not detected when the subgroup is mixed
with women without this polymorphism.
DrTomasson mentions that we should have referred to the paper
by T6masson and Tomasson (1996) (TT) and discussed the differ-
ence between the results. We regret not having done so. However,
with respect to our aim, the TT study was not more relevant than a
very large body of other studies on OC use and breast cancer in
which young users had not been considered separately. The TT
study neither aimed at investigating a possible effect of OC use at
young age nor could it detect such an effect because of the small
number ofcases with that exposure at the time ofthe study, the last
year of diagnosis being 1989. In our study, based on the same
population 5 years later, there were 81 cases in the subgroup bome
after 1950, of which only 27 had been diagnosed before 1990.
Another important difference between the two studies was that in
the TT study, the information used in the analysis was neither
restricted to answers given before diagnosis nor to exposure before
the diagnosis ofbreast cancer, hence the study was not prospective
in that sense. This may have biased their results in comparisons
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concerning cases at child-bearing ages, because women can be
expected to discontinue OC use after the diagnosis of breast
cancer. This could explain their unusual finding of a significantly
lower mean duration of OC use for cases than for controls in the
youngest age groups. Yet another difference between the studies
was that TT did not match on age at interview as we did, nor did
they adjust for it in the analysis.
In our study there was a statistically significant interaction
between the variables 'year of birth' and 'duration of oral contra-
ceptive use' (P = 0.04), when tested in a conventional way by
including in the multivariate model a multiplication factorbetween
the two variables, as described in the Methods section. On the
other hand, an interaction term between 'age at diagnosis' and
'duration oforal contraceptive use' was not statistically significant
(P = 0.41). Therefore, it seems more logical to interpret the effect
demonstrated in Table 2 as a birth cohort effect rather than as an
age effect.
Dr T6masson estimates, based on Table 2, an OR of 0.66 for
breast cancer, for use > 4 years vs < 4 years for the cohort
1945-1952, thus indicating a protective effect in the older birth
cohorts. Using the same model that our results were based on,
the OR for this cohort was 0.90 with P = 0.65, thus there is no
indication of a statistically significant protective effect in the
older birth cohorts.
In his letter Dr Tomasson's speculations around equations 1 and
2 draw attention to an important subject, that is the critical age for
the postulated tuming point in risk for women using OCs at 'young
age'. The critical age at first use is not necessarily age 20 years.
Equations 1 and 2 vary according to the proportion of women
starting OC use before age 16-19 years:
proportion starting < 20 years in cohorts
proportion starting < 20 years in cohorts
proportion starting < 19 years in cohorts
proportion starting < 19 years in cohorts
proportion starting < 18 years in cohorts
proportion starting < 18 years in cohorts
proportion starting < 17 years in cohorts
proportion starting < 17 years in cohorts
proportion starting < 16 years in cohorts
proportion starting < 16 years in cohorts
1945-50
1951-67
1945-50
1951-67
1945-50
1951-67
1945-50
1951-67
1945-50
1951-67
Equations 1 and 2 result in OR = 0.24 and OR* = 2.68, with a ratio of 11.2
Equations 1' and 2' result in OR = 0.58 and OR* = 2.90, with a ratio of5.0.
Equations 1" and 2" result in OR = 0.79 and OR* = 3.73, with a ratio of4.7.
Equations 1"' and 2"' result in OR = 0.90 and OR* = 5.90, with a ratio of6.5.
Equations 1"" and 2"" result in OR = 1.0 and OR* = 17.7, with a ratio of 17.7.
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All these estimates are necessarily unprecise, being based on
small numbers. They could be used in connection with specula-
tions regarding the critical age at first use, arguing that a very high
ratio between OR* and OR is unlikely, thus making age 18 years
an appealing choice.
Finally, we do not completely agree with DrTomasson when he
claims that the two Icelandic studies and the results of the
Collaborative Group on Hormonal Factors in Breast Cancer
(1996) all show that use ofOC has very little impact on the risk for
breast cancer. We feel that there is still aquestion mark concerning
the effects ofOC use atyoung age. Our study, as well as the one by
the Collaborative Group give rise to some concern about this
matter. The study of the Collaborative Group also found an
increased risk in young users and, to quote the paper, 'The avail-
able data for use beginning before age 20 indicate that there is no
substantial increase of breast cancer risk in this subgroup more
than 5 years after cessation of use, but virtually all the existing
information relates to women younger than 45. In the next decade
women who began use as teenagers will reach their late 40s and
early 50s, when breast cancer is more common. When the new
data on the long-term effects ofearly use become available it will
be necessary to re-examine the worldwide evidence'.
L Tryggvadottir, H Tulinius and GB Gudmundsdottir
Epidemiological Unit, kcelandic CancerRegistry,
kcelandic Cancer Society, PO Box 5420, 1S-125Reykjavik, kceland
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How best,to express oestrogen receptor activity
Sir
With reference to the recenteditorial by RA Hawkins (1996), I feel
compelled to take issue with the opening sentence and the rather
provocative statement 'The oestrogen receptor (ER), discovered
around 1960 ...' and the references cited therein. Whatever the
controversy surrounding methods ofassay and the clinical signifi-
cance of ER as a prognostic and predictive factor, its nascent
details are worthy ofclarification.
The physiological basis for responses to early forms of ablative
endocrine therapies was unknown atthe time oftheir clinical intro-
duction (Schinzinger, 1889; Beatson, 1896). Oestrogens were only
isolated in crystalline form in 1936 from sows' ovaries by
MacCorquadale and co-workers (1936). Despite the isolation of
oestrogens and animal data implicating these substances in both
initiation and promotion of mammary tumours in rodents (Eisen,
1932; Lacassagne, 1932), evidence for a direct role in normal
breast function and development of mammary neoplasia was
lacking. Glascock and Hoekstra published a seminal paper in 1959
on the selective accumulation ofradiolabelled synthetic oestrogens
in target organs that respond to these hormones. A tritiated
oestrogen derivative of high specific activity selectively localized
in the mammary glands, uterus, vagina and pituitary glands
of immature goats and sheep. This was important corroborative
data linking oestrogen with normal breast physiology, and subse-
quently the selective uptake ofradiolabelled systemic oestradiol by
7,12-dimethylbenzanthracene (DMBA)-induced rat mammary
tumours was demonstrated (King, 1965; Mobbs, 1966; Terenius,
1968). However, although the existence of putative oestrogen
receptors was postulated they were not identified in these experi-
ments.
The formal discovery of the oestrogen receptor (ER) came in
the mid to late 1960s by groups ledby Gorski and Jensen (Toft and
Gorski, 1966; Jensen et al, 1968). These workers carried out
further experiments that consolidated understanding ofoestrogen-
stimulated growth. Radiolabelled oestradiol incubated with uterine
tissue of immature rats was bound to cytosolic and nuclear frac-
tions. The oestradiol in the cytosol was associated with a specific
oestrogen-binding protein that was undetectable in the nuclear
fraction. These findings led to formulation of an early model for
oestrogen-mediated events in which oestrogen interacted directly
with target cells via cytoplasmic receptors. Subsequent transloca-
tion of the ligand-receptor complex to the nucleus was followed
by interaction with DNA and modulation of gene transcription.
The presence or absence of ER was consistent with data showing
that uptake of tritiated oestradiol by breast tumour samples was
essentially 'all or none' - tumours accumulated oestradiol either
significantly orhardly atall. This preliminary model has now been
refined and, in particular, evidence now suggests that native forms
of the unoccupied ER do reside within the nucleus. The precise
conditions that determine nuclear localization remain to be eluci-
dated (Jensen, 1991).
These observations have heralded the modern era of endocrine
therapy in which the clinical response of advanced breast cancers
could be predicted from the ER content of metastatic lesions
(McGuire, 1975) and later of primary tumours (Campbell, 1981).
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